Page 80 - 2021_03-Haematologica-web

M. Autio et al.
AB
C
DEF
Figure 5. A high proportion of T cells expressing immune checkpoint molecules in the tumor microenvironment (TME) correlates with worse outcome in patients with diffuse large B-cell lymphoma (DLBCL). (A) The multiplex immunohistochemistry (mIHC) data from the Nordic Lymphoma Group (NLG) Trial cohort was clustered according to the proportions of TIM3+ T cells and LAG3 expressing CD8+ T cells. (B) Kaplan-Meier (log-rank test) survival plots depict overall survival (OS) in months (mo) in the groups with high and low amounts of these immune checkpoint molecule-expressing T cells in the NLG Trial cohort. (C) Unsupervised hierarchical clus- tering of T cells expressing immune checkpoint molecules in the Helsinki diffuse large B-cell lymphoma (HEL-DLBCL) cohort. (D) Kaplan-Meier (log-rank test) survival plots depict OS in the groups with high and low amounts of T cells expressing TIM3, LAG3 and PD1 in the HEL-DLBCL cohort. (E and F) Kaplan-Meier (log-rank test) survival plots depict OS in the groups with a high and low expression of immune checkpoint molecules in patients with an International Prognostic Index (IPI) score over 1 (E) and in patients with non-GCB type DLBCL (F) in the HEL-DLBCL cohort. N=46 for (A and B) and N=119 for (C-F). (Samples having tissue microarrays spots with poor quality for any of the phenotypes were removed from the clustering and survival analyses).
726
haematologica | 2021; 106(3)